MX341243B - Formulacion que comprende una enzima de degradacion de proteoglicano. - Google Patents

Formulacion que comprende una enzima de degradacion de proteoglicano.

Info

Publication number
MX341243B
MX341243B MX2011004013A MX2011004013A MX341243B MX 341243 B MX341243 B MX 341243B MX 2011004013 A MX2011004013 A MX 2011004013A MX 2011004013 A MX2011004013 A MX 2011004013A MX 341243 B MX341243 B MX 341243B
Authority
MX
Mexico
Prior art keywords
chondroitinase
methods
purifying
stable formulations
purifying chondroitinase
Prior art date
Application number
MX2011004013A
Other languages
English (en)
Inventor
O Caggiano Anthony
G Sheptovitsky Yelena
Kasperbauer Sarah
A Gruskin Elliott
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MX341243B publication Critical patent/MX341243B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a una formulación que comprende una enzima de degradación de proteoglicano seleccionada del grupo que consiste de condroitinasa ABCII, condroitinasa AC, condroitinasa B, o enzimas de mamífero con actividad tipo condroitinasa tal como Hyal 1, Hyal 2, Hyal 3, Hyal 4, y PH20 y el amortiguador fosfato que tiene una concentración de 750 - 1000 Mm, en donde la formulación es estable por al menos 24 horas.
MX2011004013A 2004-05-18 2006-11-17 Formulacion que comprende una enzima de degradacion de proteoglicano. MX341243B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57203004P 2004-05-18 2004-05-18
US62188204P 2004-10-25 2004-10-25

Publications (1)

Publication Number Publication Date
MX341243B true MX341243B (es) 2016-08-12

Family

ID=35428854

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA06013345A MXPA06013345A (es) 2004-05-18 2005-05-18 Metodos para purificar condrointinasa y sus formulaciones estables.
MX2011004013A MX341243B (es) 2004-05-18 2006-11-17 Formulacion que comprende una enzima de degradacion de proteoglicano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA06013345A MXPA06013345A (es) 2004-05-18 2005-05-18 Metodos para purificar condrointinasa y sus formulaciones estables.

Country Status (8)

Country Link
US (1) US8226941B2 (es)
EP (1) EP1750757B1 (es)
JP (1) JP4926962B2 (es)
AU (1) AU2005244933B2 (es)
CA (1) CA2566731C (es)
ES (1) ES2411504T3 (es)
MX (2) MXPA06013345A (es)
WO (1) WO2005112986A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301564A1 (en) 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
CA2493509C (en) 2002-06-03 2010-03-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
ES2393748T3 (es) 2005-09-26 2012-12-27 Acorda Therapeutics, Inc. Composiciones y métodos de uso de condroitinasa ABCI mutantes
WO2008045970A2 (en) 2006-10-10 2008-04-17 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
JP2011136911A (ja) * 2009-12-25 2011-07-14 Tosoh Corp 甲状腺刺激ホルモンレセプターの安定化方法
EP2900256A1 (en) * 2012-09-25 2015-08-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Treatment of central nervous system (cns) injury
WO2018200290A1 (en) * 2017-04-24 2018-11-01 Advantek Serum Laboratories Ltd. Production of high purity chondroitinase abc
US9796970B1 (en) 2017-04-24 2017-10-24 Advantek Serum Laboratories Ltd. Production of high purity chondroitinase ABC

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757964A (en) 1986-07-17 1988-07-19 Hughes Aircraft Company Method for controlling the attitude of a spinning body in orbit
US5270194A (en) * 1989-08-31 1993-12-14 Instrumentation Laboratory Spa Stabilized glucose oxidase from Aspergillus Niger
WO1991006303A1 (en) 1989-10-27 1991-05-16 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5496718A (en) * 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
US7008783B1 (en) 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
AU697156B2 (en) * 1993-04-23 1998-10-01 American Cyanamid Company Cloning and expression of the chondroitinase I and II genes from (p. vulgaris)
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995013091A1 (en) 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Methods of repairing connective tissues
US5498536A (en) * 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
EP0704532B1 (en) 1994-06-10 2002-09-11 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
US6093563A (en) * 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5997863A (en) * 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6326166B1 (en) * 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6313265B1 (en) * 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
US5869301A (en) * 1995-11-02 1999-02-09 Lockhead Martin Energy Research Corporation Method for the production of dicarboxylic acids
JP3702450B2 (ja) 1996-12-18 2005-10-05 ニプロ株式会社 乳酸脱水素酵素測定用試薬
US6200564B1 (en) * 1997-04-11 2001-03-13 J. Thomas Lamont Pharmaceutical compositions containing chondroitinase and uses therefor
DE69829605T2 (de) * 1997-05-02 2006-02-09 Seikagaku Corp. Chondroitinase enthaltende Zusammensetzungen
JP4172842B2 (ja) 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
ES2185117T3 (es) * 1997-08-22 2003-04-16 Seikagaku Kogyo Co Ltd Agente terapeutico para disco intervertebral herniado.
US20010006630A1 (en) 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6153187A (en) * 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
JP4319348B2 (ja) 1997-10-17 2009-08-26 ジェネンテック・インコーポレーテッド ヒトトール相同体
WO1999040787A1 (en) 1998-02-13 1999-08-19 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
WO1999046368A2 (en) 1998-03-13 1999-09-16 Biomarin Pharmaceuticals Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
CA2322748A1 (en) 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
EP1109919A2 (en) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
ATE305310T1 (de) * 1998-10-06 2005-10-15 Stryker Corp Verwendung von op-1 zur herstellung einer pharmazeutischen zusammensetzung zur reparatur von nicht-gelenksknorpeldefekten eines säugers
EP1157275A4 (en) 1999-02-28 2003-01-15 Univ Washington NEW TRANSDUCTION MOLECULES AND METHOD FOR USING THE SAME
AU3883800A (en) 1999-04-02 2000-10-23 Eli Lilly And Company Hob-bp2h compositions, methods and uses thereof
SE9901428D0 (sv) 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
KR100659477B1 (ko) 1999-06-08 2006-12-20 리제네론 파라마큐티칼스 인코포레이티드 개선된 약물동태학적 성질을 가지는 변형된 키메라 폴리펩티드
WO2001039795A2 (en) 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
JP2004504064A (ja) 2000-06-22 2004-02-12 アムジエン・インコーポレーテツド Ｉｌ−１７分子およびその用途
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
ATE532874T1 (de) 2001-02-15 2011-11-15 Univ Chicago Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
WO2003000901A2 (en) 2001-06-26 2003-01-03 Decode Genetics Ehf. Nucleic acids encoding protein kinases
KR20040021697A (ko) * 2001-08-13 2004-03-10 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 신경 조직 복구를 증진시키는 물질 및 방법
US20030049258A1 (en) 2001-09-11 2003-03-13 Martin Ungerer Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
US20040214190A1 (en) 2001-10-09 2004-10-28 Butz Eric A Mammalian c-type lectins
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
EP2301564A1 (en) 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US7807618B2 (en) 2002-05-20 2010-10-05 The Board Of Regents Of The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues
CA2493509C (en) * 2002-06-03 2010-03-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US7163545B2 (en) 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
JP4527950B2 (ja) * 2002-08-09 2010-08-18 シスメックス株式会社 脂質測定試薬
US7074581B2 (en) * 2002-08-09 2006-07-11 Sysmex Corporation Reagent for assaying lipid
CA2495121A1 (en) 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
EP1530643B1 (en) 2002-08-15 2011-05-04 Acorda Therapeutics, Inc. Chimeric protein
JP2004113166A (ja) 2002-09-27 2004-04-15 Mitsui Chemicals Inc ハロペルオキシダ−ゼ活性の安定化方法
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
MX348062B (es) * 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA05012305A (es) 2003-05-16 2006-04-18 Acorda Therapeutics Inc Composiciones y metodos para el tratamiento de lesiones del snc.
EP1737954A2 (en) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
ES2393748T3 (es) 2005-09-26 2012-12-27 Acorda Therapeutics, Inc. Composiciones y métodos de uso de condroitinasa ABCI mutantes

Also Published As

Publication number Publication date
MXPA06013345A (es) 2008-10-31
EP1750757A2 (en) 2007-02-14
AU2005244933A1 (en) 2005-12-01
CA2566731C (en) 2012-07-24
WO2005112986A2 (en) 2005-12-01
US8226941B2 (en) 2012-07-24
JP4926962B2 (ja) 2012-05-09
WO2005112986A3 (en) 2009-04-16
CA2566731A1 (en) 2005-12-01
AU2005244933B2 (en) 2011-08-04
ES2411504T3 (es) 2013-07-05
US20080311642A1 (en) 2008-12-18
EP1750757A4 (en) 2010-01-13
EP1750757B1 (en) 2013-03-13
JP2008505661A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
MX341243B (es) Formulacion que comprende una enzima de degradacion de proteoglicano.
WO2008091740A3 (en) Polyelectrolyte precipitation and purification of antibodies
NO20071811L (no) Rotasjonsseparator, samt fremgangsmate
DK1737945T3 (da) Fremgangsmåde til oprensning af plasmid-DNA
WO2013177115A3 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2002083710A3 (en) Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
WO2007133596A3 (en) Method and system for production of zein and/or xanthophylls using chromatography
MX2009005012A (es) Una forma pura de rapamicina y procedimiento para la recuperacion y purificacion de la misma.
HK1138290A1 (en) Method of purification of hydrophobic proteins
GB0406281D0 (en) A system for extracting tetrodotoxin
WO2003039702A3 (en) Methods and compositions for chromatography
WO2014005014A3 (en) Purification of iduronate-2-sulfatase
BRPI0413907A (pt) método de preparação de plasmìdeo dna de grau farmacêutico
DK0975790T3 (da) Ny fremgangsmåde til isolering af polysaccharider
DE59912722D1 (de) Kontinuierliches verfahren zur trennung von stoffen nach molekülgrösse
NO20015703D0 (no) Fremgangsmåter for DNA rensing og renset DNA
MY190069A (en) Method and system for purification of natural gas using membranes
PL1960521T3 (pl) Sposób i zestaw do rozdzielania, oczyszczania i odzyskiwania długo- i krótkołańcuchowych kwasów nukleinowych
HK1047754A1 (en) Separation of fibrinogen from plasma proteases
WO2006127973A3 (en) Methods for separating and analyzing anionic compounds
BR9810650A (pt) Vetor para expressão de proteìna heteróloga e métodos para extrair proteìna recombinante e para purificar insulina recombinante isolada
CN104558101A (zh) 一种海绵动物水溶性肽类的制备方法
WO2002012533A3 (en) Fermentation and purification of mycolactones
TW200640378A (en) A process for recycling and reusing waste medium for mushroom culture
TW200506057A (en) Transient production of pharmaceutically important proteins in plants